Analysis of MMP2 promoter polymorphisms in childhood obesity

BMC Research Notes

Lynnette R Ferguson¹  Edwin A Mitchell²  John MD Thompson²  Dug Yeo Han¹  Angharad R Morgan¹ 

[1] Nutrigenomics New Zealand, New Zealand;Department of Paediatrics, FMHS, The University of Auckland, New Zealand

关键词: genetic association;    matrix metalloproteinase-2;    percentage body fat;    childhood obesity;   

Others  :  1167364
DOI  :  10.1186/1756-0500-4-253

 received in 2011-02-09, accepted in 2011-07-21,  发布年份 2011

【 摘 要 】

Background

Several lines of evidence suggest a possible functional role of Matrix metalloproteinase -2 (MMP-2) in obesity. The aim of this study was to evaluate the role of MMP-2 promoter polymorphisms in percentage body fat (PBF) as a measure of childhood obesity in a New Zealand population.

Findings

546 samples from the Auckland Birthweight Collaborative (ABC) study were genotyped for the three MMP-2 promoter SNPs -1306 C/T (rs243865), -1575G/A (rs243866) and -790 T/G (rs243864) using the Sequenom genotyping platform. The results demonstrated that an MMP-2 promoter haplotype is associated with PBF in New Zealand 7 year old children.

Conclusion

We have previously determined that environmental factors are associated with differences in PBF in this study group, and now we have demonstrated a possible genetic contribution.

【 授权许可】

   
2011 Morgan et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lee YS: Consequences of childhood obesity. Ann Acad Med Singapore 2009, 38(1):75-77.
• [2]Whitaker RC, Wright JA, Pepe MS, et al.: Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997, 337:869-873.
• [3]Micić D: Obesity in children and adolescents--a new epidemic? Consequences in adult life. J Pediatr Endocrinol Metab 2001, 14(Suppl 5):1345-1352.
• [4]Hall DM, Cole TJ: What use is the BMI? Arch Dis Child 2006, 91:283-286.
• [5]Blair NJ, Thompson JMD, Black PN, et al.: Risk factors for obesity in 7-year-old European children: the Auckland Birthweight Collaborative Study. Arch Dis Child 2007, 92(10):866-871.
• [6]Sternlicht MD, Werb Z: Matrix metalloproteinase. In Guidebook to the extracellular matrix, anchor and adhesion proteins. Edited by Kreis T, Vale R. Oxford University Press New York; 1999:503-603.
• [7]Brown LM, Fox HL, Hazen SA, et al.: Role of the matrixin MMP-2 in multicellular organization of adipocytes cultured in basement membrane components. Am J Physiol 272(3 Pt 1):C937-49.
• [8]Bouloumié A, Sengenès C, Portolan G, et al.: Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001, 50:2080-2086.
• [9]Lijnen HR: Plasmin and matrix metalloproteinases in vascular remodelling. Thrombosis and Haemostasis 2001, 86:324-333.
• [10]Lijnen HR, Maquoi E, Demeulemeester D, et al.: Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thrombosis and Haemostasis 2002, 88:345-353.
• [11]Lagente V, Boichot E: Matrix Metalloproteinases in Tissue Remodelling and Inflammation (Progress in Inflammation Research). 2008, 1-168.
• [12]Price SJ, Greaves DR, Watkins H: Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001, 276:7549-7558.
• [13]Harendza S, Lovett DH, Panzer U, et al.: Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003, 278:20490-20499.
• [14]Vasku A, Goldbergova M, Izakovicova Holla L, et al.: A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol 2004, 22:585-591.
• [15]Thompson JM, Clark PM, Robinson E, et al.: Risk factors for small-for-gestational-age babies: The Auckland Birthweight Collaborative Study. J Paediatr Child Health 2001, 37(4):369-375.
• [16]Schaefer F, Georgi M, Zieger A, Schärer K: Usefulness of bioelectric impedance and skinfold measurements in predicting fat-free mass derived from total body potassium in children. Pediatr Res 1994, 35(5):617-624.
• [17]Jurinke C, van der Boom D, Cantor CR, et al.: The use of massARRAY technology for high throughput genotyping. Adv. Biochem. Eng. Biotechnol 2002, 77:57-74.
• [18]Storm N, Darnhofer-Patel B, van der Boom D, et al.: MALDI-TOF mass spectrometry-based SNP genotyping. Methods Molecular Biology 2003, 212:241-262.
• [19]Balding DJ: A tutorial on statistical methods for population association studies. Nat Rev Genet 2006, 7(10):781-791.
• [20]Cordell HJ, Clayton DG: Genetic association studies. Lancet 2005, 366:1121-1131.
• [21]Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
• [22]Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al.: The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229.
• [23]Ihaka R, Gentleman R: R: A language for data analysis and graphics. Journal of Computational & Graphical Statistics 1996, 5(3):299-314.
• [24]Ober C, Leavitt SA, Tsalenko A, et al.: Variation in the interleukin 4-receptor alpha gene confers susceptibility to asthma and atopy in ethnically diverse populations. Am J Hum Genet 2000, 66:517-526.
• [25]Bottini N, Borgiani P, Otsu A, et al.: IL-4 receptor alpha chain genetic polymorphism and total IgE levels in the English population: two-locus haplotypes are more informative than individual SNPs. Clin Genet 2002, 61:288-292.
• [26]Han DH, Kim SK, Kang S, et al.: Matrix Metallopeptidase 2 Gene Polymorphism is Associated with Obesity in Korean Population. Korean J Physiol Pharmacol 2008, 12(3):125-129.
• [27]Van Hul M, Lijnen HR: A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008, 6(7):1198-206.
• [28]Glowinska-Olszewska B, Urban M, Florys B: Selected matrix metalloproteinases (MMP-2 and MMP-9) in obese children and adolescents. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2006, 12:179-183.
• [29]Glowinska-Olszewska B, Urban M: Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007, 56:799-805.
• [30]Derosa G, Ferrari I, D'Angelo A, et al.: Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008, 15(4):219-224.